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Abstract
Aim: Despite the extensive experience with minimal invasive stone therapy, there are still dif-
ferent views on the ideal management of renal stones.
Materials and Methods: Analysis of the literature includes more than 14,000 patients. We have
compared these data with long-term results of two major stone centers in Germany. The results
have been compared concerning the anatomical kidney situation, stone size, stone localization
and observation time.
Results: According to the importance of residual fragments following extracorporeal shock
wave lithotripsy (ESWL), we have to distinguish between clinically insignificant residual frag-
ments and clinically significant residual fragments (CIRF). 24 months following ESWL stone
passage occurs as a continous process, and if there are no clinical symptoms, any endoscopic
procedure should be considered as overtreatment. According to these results, stone-free rates
of patients increase in longer follow-up periods. Newer ESWL technology has increased the
percentage of CIRF.
Conclusion: We consider ESWL in most patients with renal calculi as first-line treatment, except
in patients with renal calculi bigger than 30 mm in diameter.
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Introduction
Management of renal calculi has changed dramatically
during the past 20 years. Minimally invasive techniques,
especially the development and introduction of extracorpo-
real shock wave lithotripsy (ESWL), virtually have re-
placed open surgical stone removal. Even large and com-
plex renal calculi may be treated effectively with these
minimally invasive techniques. Surgical removal of renal
stones had been reserved for those patients with persistent
symptoms or recurrent urinary tract infections associated
with the presence of the stone. Except for patients with
treatment of calyceal calculi by ESWL mainly concerns three aspects:
(1) the rationale of ESWL for small asymptomatic calculi; (2) the lim-
its of ESWL monotherapy of calyceal calculi in case of associated
anatomical disorders (i.e. calyceal infundibular stenosis, horseshoe
kidneys), and (3) the overall efficacy of ESWL for calyceal calculi, de-
pending on stone size and localization. Additionally, we were focusing
on the specific anatomical situation of the collecting system. In pa-
tients with normal renal anatomy, the efficacy of ESWL with respect to
stone size, observation time and stone localization was examined.
Based on these results, a definition of clinically insignificant residual
fragments was worked out in contrast to significant residual fragments
resulting in an algorithm for the management of renal calculi.
Comparison of Our Own Clinical Results
The above-mentioned study of the literature was supplemented 
by the analysis of 2,642 patients treated from 1995 to 1997 at two
German institutions (Department of Urology, Klinikum Heilbronn,
Teaching Hospital of the University of Heidelberg/Department of
Urology, Stadtkrankenhaus Harlaching, Teaching Hospital of the Uni-
versity of Munich). Between 1995 and 1997, ESWL was performed in
both institutions either by the Siemens Multiline lithotripter, the
Siemens Lithostar Plus or the Storz Modulith lithotripter. All three
lithotripters have electronic shockwave elements and belong to the
third-generation machines. The technical details are summarized in
table 1.
Results
In the following, the results of the review of the literature
are presented and compared with the extensive experience
of both German stone centers. Moreover, they are discussed
on the basis of the current literature worldwide.
ESWL for Small Asymptomatic Calyceal Calculi
ESWL has revolutionized the treatment strategy of
urolithiasis worldwide [14, 15]. In Germany, there has been
a decreasing use of ESWL for larger pelvic stones and an in-
creasing use for smaller calyceal and ureteral calculi [16].
In the US Cooperative Study published in 1986, 36% of the
stones were smaller than 10 mm [7], whereas in recently
presented studies in more than 50% of the patients calculi
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complete staghorn calculi, in most of these patients a com-
bined percutaneous nephrolithotomy (PCNL) and ESWL
should be recommended as the first-line treatment [1]. Al-
though open surgical stone removal is performed infre-
quently, a clear understanding of the subtle renal anatomy
aids the urologist in more effectively treating patients with
renal calculi and in limiting surgical complications.
Most discussion is about the treatment of calyceal cal-
culi. 20 years ago the term nonobstructive calyceal stone
was introduced to justify the conservative management of
asymptomatic calculi [2, 3]. With the advent of PCNL, the
approach to calyceal calculi has become more liberal. En-
dourological techniques were developed to remove stones
from calyces and calyceal diverticula [4, 5]. ESWL has fur-
ther simplified the treatment of calyceal calculi, so that the
majority have become eligible for treatment [5–9]. Howev-
er, the results of ESWL were not as satisfactory as for renal
pelvic stones, particularly in cases of concrements in the
inferior calyces or in calyceal diverticula which are associ-
ated with infundibular stenosis [10, 11]. Based on a review
of the literature, Lingeman et al. [12] recently advocated
PCNL for the majority of lower-pole calculi as primary ap-
proach. On the other hand, Ilker et al. [13] recently con-
cluded, that ‘in spite of its lower stone-free rates, ESWL,
with its lower morbidity, may still be considered as an 
acceptable treatment modality, especially when there is a
patient desire for conservative treatment’. Based on an ex-
tensive review of the literature and our own clinical experi-
ences, we try here to define guidelines for the management
of renal stones with special emphasis on a wide clinical ac-
ceptance by urologists and patients.
Materials and Methods
Analysis of the Literature
An analysis concerning more than 14,000 patients from the litera-
ture worldwide presented in 105 articles was elaborated with special
emphasise on long-term results of ESWL of renal calculi. Herein, the
Generator Localization Focus aperture Clinical
+focusing
mm cm
introduction
Siemens electromagnetic coaxial US 80E6 12 1989
Lithostar Plus acoustic lens 2 X-ray tubes
Storz electromagnetic coaxial US 28E6 40 1989
Modulith SL 20 Paraboloid integrated X-ray
Siemens
Multiline electromagnetic in line X-ray 80E5 16 1994
Table 1. Lithotriptors used in thist study
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were less than 10 mm in diameter [16–18]. These data
demonstrate that there is a trend for treating small calyceal
calculi.
Before the ESWL era, the urologic dogma was strongly
opposed to the removal of nonobstructing calyceal calculi.
Most patients were appropriately reassured that the calculus
was not causing renal damage nor was it the direct cause of
flank discomfort [4]. In 1985, Hübner et al. [19] presented a
follow-up study on patients with untreated nonobstructive
small calyceal calculi prior to the ESWL era with an obser-
vation time ranging from 1 to 21 years: in 68% of these pa-
tients calculi were associated with urinary tract infections,
and 51% of these patients suffered from renal colic. Inter-
estingly, 40% of the patients ultimately required an inter-
vention, and only in 16% of these patients did the stones
pass spontaneously.
In 1986, Brannen et al. [4] reported 95% resolution of
preoperative pain after PCNL. They intensively advocated
minimally invasive stone removal for small symptomatic
calyceal calculi, if possible with even less traumatic ESWL.
In 1988, Mee and Thüroff [20] presented the data of 22 pa-
tients with small nonobstructive calyceal stones treated by
ESWL. 84% of these patients were rendered stone-free and
91% achieved complete or significant relief of pain. In
1991, Hendrikx et al. [21] studied the efficacy of ESWL
with small symptomatic calyceal stones in 37 patients: in
84% of the patients the stone could be successfully disinte-
grated, but the 3-month stone-free rate was only 50% and
depended on stone localization (75%) for upper vs. 42% for
lower pole stones). 52% of the patients were symptom free,
and 32% both stone and symptom free after 3 months. Our
own recent study [16] with 445 calculi less than 10 mm
treated with two third-generation lithotriptors (Siemens
Lithostar Plus, Modulith SL 20) showed 84% and 90%
stone-free rates 12 months after ESWL for stones smaller
than 5 mm and calculi less than 10 mm, respectively (fig. 1).
Only 2% of the patients required auxiliary measures after
ESWL [16].
Fig. 1. Stone-free rates after ESWL of small
caliceal calculi using the Modulith SL 20 (a)
and Siemens Lithostar Plus (b), n = 445.
a
b
In summary, most of these data confirm the overall effi-
cacy of ESWL for small nonobstructive stones. These re-
sults led to a significant expansion of the indications for
ESWL as compared with early series [6, 7]. The question
remains whether small nonobstructive asymptomatic stones
(d5 mm) should be treated primarily with ESWL. We
know that about 50% of these stones will become ureteric
calculi [19]. The rationale for early treatment with ESWL is
that it will prevent any serious problems if stones pass down
the ureter. A recent report supporting the opposing view to
the aforementioned early retreatment shows that the mor-
bidity of ESWL at 12 months of follow-up is negligible
[16]. Such stones might be considered as ideal for outpa-
tient ESWL treatment, with success rates of 90% [16].
Therefore, this option should be discussed individually with
each patient.
Overall Efficacy of ESWL for Calculi with Normal Renal
Anatomy (table 2, 3)
In patients with normal anatomy, stone disintegration is
not the foremost problem, but rather passage of the debris
(in contrast to the in situ treatment of ureteral calculi). The
treatment goal for any calculus is to render the patient free
of symptoms and stones and to preserve renal function. The
choice of an appropriate treatment strategy for calyceal cal-
culi depends on many distinct elements. Among these fac-
tors are stone size, location and composition as well as the
anatomy of the urinary tract and the patient’s overall medi-
cal condition [25]. Many patients, however, may benefit
from stone disintegration that results in minor residual frag-
ments, so-called ‘clinically insignificant residual frag-
ments’ (CIRF) (table 4). Changing the therapeutic end
points would have a major impact on treatment strategies
for calyceal stones.
Approximately 40–50% of all treated single urinary cal-
culi are located within the calyces, and most of these are
found in the lower calyx [8, 17, 34, 46–48] (table 5). This
distribution has not changed during the last decades [89].
The overall results of ESWL for the management of ca-
lyceal calculi depend significantly on the localization and
size of the stone [8, 13, 49–51] (tables 6–8). During the last
decade, the main importance of ESWL treatment was to
achieve a complete stone-free status, ignoring the fact that
more and more patients benefit from successful stone disin-
tegration but with minor residual fragments, the so-called
CIRF (table 9). Of course, the acceptance of this change of
therapeutic end points would have a major impact on treat-
ment strategies for all calyceal stones [90, 91].
Stone Size. However, the indication for ESWL mono-
therapy in the management of calyceal calculi should also
consider the stone size (table 7): The results of ESWL for
stones up to 10 mm in diameter are satisfactory independent
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Table 2. Efficacy of ESWL for calyceal diverticula calculi
Author n Follow- Stone- Symptom-
up free free
months % %
Wilbert et al. [27] 16 3 20 n.a.
Psihramis and Dretler [31] 10 6 20 70
Ritchie et al. [32] 20 4 25 75
Kriegmair et al. [30] 10 6 10 50
Jones et al. [29] 26 3 4 36
Hendrikx et al. [28] 15 3 13 60
Streem and Yost [26] 19 24 58 86
Total (mean) 129 3–4 17 60
Table 3. Efficacy of ESWL for horseshoe kidneys
Author n Stone-free Lithotripter
Semerci et al. [42] 18 9 Dornier MLP 9000
Alkibay et al. [37] 22 16 Siemens Lithostar Plus
Baltaci et al. [38] 7 5 Dornier MLP 9000
Knopf et al. [39] 18 9 Dornier HM-3
Table 4. Clinically insignificant fragments
(CIRF) – definition
4 mm or less residual fragments after ESWL
Calcium oxalate/phosphate calculi
Normal anatomy of the upper urinary tract
No urinary tract infection
No symptoms after ESWL
No adjuvant therapy
Table 5. Distribution of calyceal stones according to size and local-
ization (according to Moon et al. [47] n = 573)
Site d10 mm 10–19 mm 20–29 mm c30 mm
Upper calix 10 7 2 0.5
Middle calix 10 5 0.5 –
Lower calix 35 24 5 1
Total 55 36 7.5 1.5
of the localization in the kidney, whereas the stone-free
rates for stones between 10 and 20 mm in diameter are de-
creasing, particularily for lower-pole stones [12, 13, 51, 52,
77]. On the other hand, there is no study showing satisfac-
tory results for ESWL monotherapy of stones larger than 30
mm in diameter. The fact that the majority (about 75%) of
larger stones (c20 mm) are found in the lower calyx (table
5) may have affected significantly the unsatisfactory overall
results for lower-pole stones [47]. Nevertheless, there is an
increasing consensus in the literature that lower-pole stones
larger than 30 mm shoule be preferably treated by PCNL
[10–12]. However, it must be emphasized that this concerns
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Status Graff Tolon Moon Rassweiler Cass
et al. [64] et al. [48] et al. [47] et al. [16] [46]
Patients, n 617 1,160 826 765 7,022
Patients with caliceal stones, n 342 304 573 357 2,537
Year of publication 1988 1991 1993 1995 1995
Localization, %
Upper calix 16 4 14 10 5
Middle calix 17 6 11 14 7
Lower calix 23 16 44 22 24
Total 56 26 69 46 36
Table 6. ESWL for calyceal calculi – stone
distribution in large series of solitary stones
Patients n Observation Stone-free, %
time
d10 mm 10–19 mm 20–29 mm c30 mm
months
Newmann et al. [49] 972 3 80 71 57 n.a.
Ilker et al. [13] 386 12 82 59 59 13
Rassweiler et al. [16] 359 12 87 72 65 17
Lingeman et al. [12]a 439 3 80 58 33 n.a.
Chen and Streem [52]a 206 24 63 46 46 13
Küpeli et al. [82]a 165 3 62 48 28b
Pacik et al. [83]a 310 3 71 46 31b
aOnly lower pole stones; ba21 mm.
Table 7. ESWL for calyceal calculi –
Stone-free rates depending on stone size
Status Newman Ilker Petterson and Graff Zanetti
et al. [49] et al. [13] Tiselius [50] et al. [64] et al. [51]
Patients, n 972 386 187 342 129
Observation time, months 3 12 12 19 12
Stone-free, %
Upper calix 75 64 85 78 70
Middle calix 71 77 65 75 59
Lower calix 59 59 78 58 39
Table 8. ESWL for calyceal calculi –
stone-free rates depending on the localiza-
tion and observation time
Table 9. Distribution of residual fragments and site of recurrent
stone formation (according to Petterson and Tiselius [50] and Kami-
hara et al. [60]
Location Residual fragments (%) after Recurrent
1 month 6 months 12 months stone (%) after22 months
Upper calix 8 7 10 20
Middle calix 10 15 14 13
Lower calix 56 69 72 60
Pelvis 6 3 2 2
Ureter 20 6 2 5
only a minority (about 7–9%) of patients suffering from re-
nal calculi [16, 47, 48, 50].
In recent times, a new treatment modality, the so-called
sandwich therapy, for patients with major stone burden, es-
pecially with staghorn calculi, was described in many stud-
ies [53–56]. Sandwich therapy was developed as a planned
endourologic approach to manage large, extensively
branched or otherwise complex calculi. Specifically, it was
designed to allow safe and effective application of minimal-
ly invasive technology to patients who might otherwise re-
quire open operative intervention or to those who would not
predictably benefit from PCNL or ESWL alone [55]. Be-
cause the risk of bleeding and sepsis with percutaneous
monotherapy is at least to some extent proportional to the
number of percutaneous tracts used, and because the poten-
tial toxicity of repeated high-dose shockwave lithotripsy is
unknown, sandwich therapy has been designed specifically
to minimize the risk of bleeding and septic complications
and to decrease the number of shockwaves otherwise re-
quired. A further goal of this treatment is to decrease the
need for prolonged nephrostomy drainage that had been a
part of earlier approaches to combined endourologic man-
agement [53].
Observation Time. Interestingly, a review of the litera-
ture suggests that the duration of follow-up (3 vs. 19
months) does not significantly influence the stone-free rates
obtained with ESWL for calyceal calculi [34, 52]. Some se-
ries, however, with a longer follow-up period, indicate the
continuous clearance of fragments for at least 24 months
following ESWL [57, 58] (fig. 2). These differences may be
explained by various diganostic methods for determination
of complete passage of fragments (plain films versus plain
films plus ultrasound) as well as the fact that particularly in
cases of small upper and middle calyceal stones, most of the
debris will pass during the first 3 months [59] or migrate to
the lower calyceal group (table 9). Finally, long-term stud-
ies always have to deal with the problem of stone recurrence
which is about 8% per 12 months [49, 59–62].
Our own clinical experience, comparable to the results of
other European centers (Vienna, Stuttgart, Mannheim),
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Status Zanetti Graff Ilker Lingeman Chen and
et al. [51] et al. [64] et al. [13] et al. [12] Streem [51]
Patients, n 49 141 219 439 206
Observation time, years 3 2 1 2 2
Stone-free, % 41 58 59 73 54
Stable/decreased, % 4 13 n.a. 9 41
Recurrence/regrowth, % 55 29 n.a. 18 5
Asymptomatic, % n.a. 84 91 n.a. 87
Symptomatic episodes, % n.a. 16 n.a. n.a. 13
Intervention n.a. 4 9 10 9
(ESWL, URS, PCNL), %
Table 10. Long-term results of ESWL for
lower pole stones
Fig. 2. Kinetics of ESWL results using two
electromagnetic lithotripters (Storz Modulith
SL 20, Siemens Lithostar Plus). Percentage
of stone-free patients within 12 months after
treatment.
clearly indicates that the passage of stone fragments does
not end after 3 months, but occurs as a continuous process
for at least 24 months (fig. 2). It must be emphasized that
stone clearance occurs asymptomatically in most of the pa-
tients  (table 10; fig. 3) and, therefore, rarely requires any
auxiliary procedures (table 11). During this period, any en-
doscopic procedure aimed at total stone clearance of
asymptomatic fragments (CIRF) should be considered as
overtreatment without any additional benefit for the patient.
Stone Localization. Although stone-free and residual
fragment rates were similar in pelvic, upper and middle ca-
lyces, patients with lower calyceal and pelvicalyceal stones
had high residual fragment rates and lower stone-free rates.
Patients with stones in the lower calyces or pelvicalyces had
high recurrence and regrowth rates [92]. Stone recurrence
occurs predominantly in the lower pole [60]. The most im-
portant reason for the relatively low stone-free rate in the
lower calyx observed in a long-term analysis of Zanetti et
al. [51], in fact, may be a bias caused by parallel recurrent
stone formation. The success of ESWL is affected by stone
location, since lower pole calyceal stones have a lower
clearance rate than other calyceal or renal pelvic stones of
similar size and composition. While Politis and Griffith [85]
reported a 69% stone-free rate with the HM3 lithotriptor,
McDougall et al. [77] described only a 57% stone-free rate
after ESWL for lower pole calculi.
Considering stones of similar composition, stone-free
rates following SWL are not solely dependent on the size of
the calculi, but rather on size together with stone location.
Stone-free rates are generally the highest for upper and mid-
dle calyceal calculi and significantly lower for lower ca-
lyceal stones. For upper and middle calyceal calculi, one
should expect stone-free rates ranging from 70 to 90%,
whereas those for such calculi located in the lower calyces
range between 50 and 70% [7, 8, 10, 34, 48, 50, 51, 61,
63–70]. The presence of residual fragments following
ESWL, necessitating multiple or adjunct procedures, is
more commonly found in association with larger stones and
lower calyceal calculi [12, 48]. There is no doubt that
ESWL represents the preferred method of treatment in this
group of patients (table 12).
The management of lower calyceal stones still remains
controversial [12]. Another option for minimally invasive
treatment of lower calyceal stones is percutaneous lithotrip-
sy. Although it is associated with a higher stone-free rate
(85%), because of its higher morbidity most urologists re-
serve this procedure for lower-pole calculi larger than 2 cm
[93]. However, this cutoff point has been recently contested.
In a prospective randomized study of 1- to 2-cm lower-pole
calculi, Elbahnasy et al. [71] recently noted that the stone-
free rate of ESWL versus percutaneous lithotripsy was 29
vs. 86%. The poor clearance of fragments after ESWL is the
greatest deterrent to its use. The reasons for lower clearance
of the fragments from the lower pole following ESWL are
unclear. It is most commonly though that the gravitiy-de-
pendent position of the lower-pole calyx precludes efficient
stone passage [58].
Thus, to improve stone clearance after ESWL, others
have suggested various regimens, such as positioning the
patient head down, ureteral stenting and flushing the lower
pole with saline during ESWL or transcutaneous needle
flushing of the lower calyx [72–74, 76, 78]. The outcome of
these procedures has been favorable. Stone-free rates have
improved up to 88% after inversion therapy. A recent study
shows that successful ESWL is highly sensitive to lower-
pole anatomy. An infundibulopelvic angle of 90° or greater,
or a short, wide infundibulum regardless of infundibu-
lopelvic angle is invariably associated with a successful
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Table 11. Auxiliary procedures after ESWL (Department of Urolo-
gy, München-Harlaching, Siemens Multiline)
Auxiliary procedure All Renal Lower
stones stones calyx
% % %
Percutaneous nephrostomy 2.5 2.0 0.8
Double J-stent 1.9 1.8 1.1
PCNL 0.1 0.1 0.0
Ureteroscopy 1.4 1.4 1.1
Total 5.9 5.3 3.0
Fig. 3. Algorithm about the fate of residual fragments after ESWL.
SF = Stone free; CIRF = clinically insignificant fragments; SIRF =
significant fragments; percentages = rate of all patients; decimals =
rate of the different subgroups. Data averaged from the studies cited
in the reference list (tables 7–10).
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outcome for calculi 15 mm or less in the lower-pole calyx.
On the other hand, a combination of unfavorable factors,
such as infundibulopelvic angle less than 90°, infundibular
lenght greater than 3 cm and infundibular width 5 mm or
less, is a poor indication with only 17% ESWL success in
these patients [71]. Based on a review of the literature with
significantly greater efficacy of PCNL, particularly for
stones larger than 10 mm in diameter, Lingeman et al. [12]
advocated a wide use of PCNL in the management of low-
er-pole stones to achieve higher stone-free rates and thus a
lower recurrence rate. Moreover, anatomical studies show-
ing an angle d90° between the lower infundibulum and the
renal pelvis in 26% and the length of the lower infudibulum
exceeding 4 mm in 60% (as signs of a gravity-unfavorable
situation) supported this strategy [58]. The long-term stone-
free rate of ESWL monotherapy for lower pole stones rang-
ing from 41 to 73% with 59% on average (table 10).
These results have mainly be produced using the Dornier
HM3 spark gap technology which required general or
epidural anesthesia. Therefore, the retreatment rate was
kept as minimal as possible. One of the main advantages of
newer lithotripter technology represents the avoidance of
anesthesia. This resulted in a wider acceptance of repeat
ESWL to improve the pulverization of the fragments and
thereby stone clearance, i.e. ‘stir up ESWL’ [75] or ‘booster
technique’ [15]. Conclusively, this strategy also increases
the percentage of clinically insignificant fragments [76–81].
Even before this era, the majority of the residual fragments
could be classified as clinically insignificant (CIRF):
75–87% of the patients remained asymptomatic and only
4–25% required a secondary intervention which mostly
consisted of a repeat ESWL [8, 13, 16, 52]. Considering re-
cent experiences with third-generation electromagnetic
lithotripters (i.e. Storz Modulith, Siemens Multiline) the
complication rate and the need for post-ESWL auxiliary
procedures could be further reduced, ranging between 3.0
and 6.5% (table 11, 13).
Adding this figure to the rate of stone-free patients, we
estimate that less than one third of patients with residual
fragments will present with any clinical problems; only
10% may require percutaneous clearance of fragments
(fig. 3). Based on this analysis, we suggest that PCNL as a
primary approach for lower-pole calculi represents over-
treatment. We share this opinion with the majority of Euro-
pean stone centers [94, 95].
Calculi with Associated Anatomic Anomalies
Anatomic abnormalities such as infundibular stenosis,
horseshoe and malrotated kidneys, and nephrocalcinosis of
medullary sponge kidney limit the efficacy of ESWL
monotherapy in patients with calyceal calculi.
Infundibular Stenosis. The symptomatic and functional
relevance of infudibular stenosis of a calyceal diverticulum
remains unclear [22]. Calyceal diverticulae are urine-filled
cavities connected to the normal collecting system by a nar-
row isthmus. The cavity is lined with nonsecretory transi-
tional epithelium and fills with urine in a retrograde fashion.
These diverticulae are generally detected incidentally on
Stone characteristics ESWL PCNL
Normal anatomy
Stone size d20 mm first approach after failure of ESWL
Stone size 20–30 mm first approach after failure of ESWL
– Upper/middle calix
– Lower calix if PCNL is contraindicated first approach
Stone size c30 mm if PCNL is contraindicated first approach
Caliceal diverticulum
Stone size c10 mm first approach (‘diagnostic’ ESWL) after failure of ESWL
Stone size c10 mm
– Patent neck if PCNL is contraindicated first approach
– Obstructed neck contraindicated if symptomatic
Table 12. Treatment recommendations for
calyceal calculi
Table 13. Complications after ESWL treatment (Department of
Urology, München-Harlaching, Siemens Multiline)
Complications All stones Renal stones Lower calyx
(n = 1,917) (n = 1,153) (n = 374)
% % %
Renal hematoma 1.3 1.9 1.6
Infected hydronephrosis 5.2 4.5 4.3
Total 6.5 6.4 5.9
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routine intravenous pyelograms and have an incidence of
less than 1% [23]. The exact cause of these anomalies is
controversial, although most agree that they are likely con-
genital, because the incidence is comparable in children and
adults. Although most calyceal diverticula remain asymp-
tomatic, flank pain, hematuria or recurrent infection may
alert one to their presence. The incidence of calculi within
calyceal diverticulae has been reported to range from 10 to
50% [22]. These calculi often cause a localized inflammato-
ry reaction that can lead to fibrosis of the diverticular wall
and possible stenosis or obliteration of the connecting isth-
mus [24]. These stones rarely pass spontaneously, yet re-
quire intervention if they become symptomatic. The most
common indication for treatment of calyceal diverticular
calculi is ipsilateral flank pain; others include recurrent in-
fection and persistent gross hematuria [25].
Early studies with a short follow-up (3–6 months) re-
vealed stone-free rates ranging from 4 to 58% (table 2).
Streem and Yost [26] reported that 11 of 19 patients were
stone free and 86% of patients remained symptom free af-
ter 2 years of follow-up. Only 1 patient developed stone re-
currence during follow-up. They concluded that ‘ESWL
for selected patients with calculi in calyceal diverticula can
achieve a relatively high initial stone-free rate and that re-
current stones may not be inevitable.’ These authors sug-
gest that criteria of selection should include the size of the
stones (maximal 10 mm) and ‘perhaps more importantly’,
the radiographically documented patent diverticular neck
[26].
Furthermore, the length of the infundibular stenosis
(maximal 10 mm) could influence the results [27]. Other-
wise, Streem and Yost [26] showed that anatomical classifi-
cation (i.e. communication to a minor calyx, infundibulum
or renal pelvis) had no impact on patient outcome. Many
studies demonstrated that 63% of the patients (36–86%) re-
mained symptom free after ESWL [26–33] (table 2). These
data sustain the concept of a ‘diagnostic’ ESWL [5, 34] as
the primary approach for most of the calyceal diverticulum
stones. More invasive procedures like percutaneous or ret-
rograde nephrolithotripsy may be reserved for special cases
with persisting stones and symptoms [26, 32, 34]. It must 
be mentioned, however, that several authors reported a
77–100% stone-fee rate and a 69–100% symptom-free rate
with PCNL as the primary approach [30, 35, 36, 98]. If eco-
nomic restraints play a major role in the future, primary 
PCNL might be more advantageous for managing a stone-
containing diverticulum [12]. However, it should be re-
membered that particularly for this indication, PCNL is a
technically difficult procedure requiring extensive endouro-
logic expertise.
In summary, it appears that ESWL monotherapy for cal-
culi in calyceal diverticula may be beneficial in selected pa-
tients and as symptomatic treatment alone. However, in
those patients with recurrent infections, in whom a stone-
free result is important, or in situations where ablation of
the diverticulum is necessary, other treatment modalities
should be used.
Horseshoe and Malrotated Kidneys. Stone-bearing
horseshoe kidney present a challenge for ESWL. The medi-
al and extremely medial location of the lower calyx makes
stone localization difficult. Passage of fragments through
the frequently high ureteropelvic junction can also be ardu-
ous. Nevertheless, surprisingly high stone-free rates rang-
ing from 50 and 85% have been reported [37–43, 79, 88]
following ESWL. Lampel et al. [40], however, emphasized
the relatively high recurrence rate of 29% after 2 years of
follow-up, exceeding the normal range by a factor 1.5–2
Schmidt et al. [41] had to perform additional percutaneous
stone removal in 28% of their patients after performing
ESWL by two lithotripters with different localization sys-
tems (fluoroscopy or ultrasound). This represents a techni-
cally demanding procedure. Concerning these studies,
many authors conclude that ESWL represents the treatment
of choice in horseshoe and malrotated kidneys with small
calyceal calculi (d20 mm) – similar to a normal anatomic
situation [34, 38, 42] (table 3). The more anterior position of
these kidneys results in a great distance between flank and
kidney with difficulties in proper positioning of the calculus
in the focal point (F2) in the standard fashion, depending on
the body habitus. Additionally, the high insertion of the
ureter with its anterior course over the isthmus may proba-
bly prevent the fragment passage after ESWL; ESWL treat-
ment in the prone positioning of such patients may be effec-
tive [44]. The presence of anatomic obstruction will
necessitate open surgery for urolithiasis in patients with
horseshoe kidney; however, in patients with normal urinary
drainage PCNL or ESWL can be considered, either singly
or as a part of combination therapy. When management is
tailored to the individual patient’s needs, results of stone
treatment can be equivalent to those in normal kidneys.
Nephrocalcinosis of Medullary Sponge Kidneys. ESWL
is ideal for treating stone-related obstruction and infection
in medullary sponge kidneys. The main advantage of
ESWL in these patients is the reproducibility and pain-free
application [15, 17, 34]. Considering the special anatomy
and high recurrence rate of stone-bearing medullary sponge
kidneys, the therapeutic pursued goal is the reduction of the
stone burden within the collecting system with improved re-
nal function and symptoms rather than achieving a stone-
free status. It must be noted that ESWL represents only one
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part of the treatment of this disease [45]. The stone clear-
ance rate in patients with lithiasis in medullary sponge kid-
neys (MSK) is not similar to that of non-MSK patients but
there is a great reduction in the frequency of renal colic and
urinary tract infection.
Discussion
It is difficult to define general guidelines. Different
philosophies exist concerning Anglo-American countries in
contrast to European and Eastern countries in treating renal
stones, especially staghorn calculi. Mattelaer et al. [95] re-
cently reported in a long-term follow-up for more than 6
years that primary ESWL monotherapy of staghorn calculi
is justified because of the comparable results with open
surgery and PCNL. Prognostic good factors are small stone
mass with most of the stone mass in the upper and middle
calices, the absence of dilatation and the absence of anatom-
ical anomalies. Ashida et al. [94] from Japan reported on 97
patients with staghorn calculi treated by ESWL monothera-
py using a Lithostar Lithotriptor (Siemens) with a stone-
free rate of 63.2% after 5 years. Lingeman [96] advocated in
a review that staghorn stones are usually best managed ini-
tially with percutaneous nephrolithotomy followed by the
addition of ESWL, if necessary. Generally, agreement exists
about ESWL as first-line treatment in lower pole calculi less
than 2 cm in diameter. Cass [97] reported that although the
stone-free rate with PCNL is higher than with SWL, the
lower complication rate, lower repeat treatment, secondary
procedure rate, the shorter hospital stay and the similar re-
current stone rate with ESWL make ESWL more clinically
effective as the primary therapy for lower pole calculi. Con-
cerning the efficacy and cost-effectiveness of ESWL for
solitary lower pole renal calculi, the Dornier HM3 shoud be
considered the initial treatment choice for most lower pole
stones of less than 2 cm [99]. In summary, ESWL is a safe
procedure with a lower morbidity than open surgery or PCN
[100, 101]. The number, location and type of the stones are
factors that influence the success of SWL [51, 101, 102]. As
mentioned before, the observation time influences the
stone-free rates [51]. The management of staghorn calculi is
one of the more demanding tasks in urology. An extensive
literature review produced a summary of the world’s expe-
rience with the treatment of staghorn calculi (table 14)
[103].
The problem for metaanalysis of results and comparison
and discussion of the literature is that a clear definition of
stone-free rates rarely exists. Does this mean CIRF or no
fragments shown by X-ray or ultrasound? Another problem
is the use of different lithotriptors. General agreement exists
about the importance of the effective quotient:
EQ1= number of stone-free patients%
100% + Re-ESWL% + auxilliary methods post-ESWL%
first described by Preminger and Clayman [104] for calcu-
lating the success rate of ESWL. The disadvantage of the
EQ1 is that not all auxilliary methods are involved, only the
post-ESWL, but in our days there is a trend for more auxil-
liary methods pre-ESWL (i.e. JJ stent). For this reason,
post-ESWL auxilliary methods are decreasing. Therefore,
Rassweiler et al. [105] developed a new modified formula
which included the kind of auxilliary management, adju-
vant as well as curative:
EQ2 = stone-free patients% – curative auxilliary methods%
100% + Re-ESWL% +% auxilliary methods pre- and post-ESWL
However, beside this, we strongly feel that the literature as
well as our own extensive experience supports the less-in-
vasive approach favoring ESWL for the majority of calculi
(table 12).
Table 14. Treatment of staghorn renal calculi [103]
SWL PNL PNL+ Open
SWL surgery
Stone-free rate, %
Median 50 73 81 82
95% confidence interval 26–74 – 68–91 57–96
Complication rate, %
Median 31 7 25 12
95% confidence interval 2–82 0–32 4–61 1–47
Procedures/patients (n)
Primary 2.1 1.5 2.8 1
Second 0.4 d0.1 d0.1 d0.1
a Includes: hydronephrosis, pneumonia, vascular injury, urinoma,
secondary unplanned intervention, sepsis and loss of kidney.
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